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Aims: To examine the prevalence of chronic kidney disease (CKD) and its associated factors in a multinational
population with type 2 diabetes mellitus (T2DM) and prior cardiovascular disease (CVD).
Methods: The LEADER trial randomized 9340 participants—81.3% with prior CVD at baseline. CKD was deﬁned
as estimated GFR b60 ml/min/1.73 m2 and/or an albumin-to-creatinine ratio ≥3.0 mg/mmol.
Results: At baseline, 51.9% of participants with prior CVD had CKD. CKD prevalence was highest in Asia (75.8%)
and lowest in Europe (43.7%) and the Middle East (43.4%). Baseline factors associated with increased CKD
prevalence included increased age, HbA1c, diabetes duration, systolic blood pressure or triglyceride levels;
greater number of antihypertensive medications; living in Asia, the Americas or Africa versus Europe; being
male; and not receiving oral antidiabetic drugs (most receiving insulin), beta-blockers or ACE inhibitors.
Factors associated with decreased CKD prevalence included increased diastolic blood pressure, no diuretic
treatment and prior myocardial infarction, angina or stroke.
Conclusions: CKD prevalence is high among patients with T2DM and prior CVD. Advanced age, long
diabetes duration, poor glycemic control, comorbidities and medications used are associated with CKD.
Our results strengthen the rationale for early screening and interventions for CKD in patients with T2DM
and prior CVD.
© 2016 The Authors. Published by Elsevier Inc. This is an open access article under the CC BY-NC-ND license
(http://creativecommons.org/licenses/by-nc-nd/4.0/).9048.
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Type 2 diabetes mellitus (T2DM) increases the risk of microvas-
cular complications (Stratton et al., 2000), confers an approximately
two-fold excess risk of cardiovascular events (Emerging Risk Factors
Collaboration et al., 2010) and is increasing in prevalence throughout
the world (International Diabetes Federation, 2015).
Chronic kidney disease (CKD) is deﬁned by albuminuria and/or
reduced estimated glomerular ﬁltration rate (eGFR) and has increased
in prevalence from 1988 to 1994 and 1999 to 2004 in the National
Health and Nutrition Examination Survey (NHANES) population
(Coresh, Astor, Greene, Eknoyan, & Levey, 2003; Coresh et al., 2007).
In European guidelines on cardiovascular disease (CVD) prevention,
CKD is acknowledged as a CVD risk equivalent (Graham et al., 2007).
Similarly, in patients with T2DM, albuminuria and reduced eGFR are
established risk factors for cardiovascular and renal events (Gerstein
et al., 2001; Ninomiya et al., 2009). However, the relationship between
CVD and CKD in T2DM is incompletely understood.
Several publications have highlighted the potential inﬂuence of race
and geographical location on the occurrence and progression of CKD in
patients with diabetes (Chandie Shaw et al., 2002; Parsa et al., 2013;
Samanta, Burden, & Jagger, 1991). For example, diabetic nephropathy
is more common among Asian than White individuals in the UK and
the Netherlands (Chandie Shaw et al., 2002; Samanta et al., 1991). In
addition, Black patients in the USA have approximately twice the risk of
end-stage renal disease (ESRD) comparedwithWhitepatients, despite a
similar prevalence of early stage CKD (Parsa et al., 2013).
The Liraglutide Effect and Action in Diabetes: Evaluation of
Cardiovascular Outcome Results (LEADER) trial was designed to assess
the cardiovascular safety of liraglutide versus placebo in patients with
T2DM and high cardiovascular risk (Marso et al., 2013). Several features
of its design allow for further study of the interplay between CVD, CKD
and other factors.
Here, we examined baseline data from the LEADER trial to evaluate
the factors associatedwith CKDprevalence in a global T2DMpopulation
with established CVD.
2. Materials and methods
The LEADER trial design, inclusion and exclusion criteria, and several
clinical characteristics of the full LEADER cohort have been previously
described (Marso et al., 2013). People with T2DM, either drug-naïve or
treated with oral antidiabetic drugs (OADs) and/or selected insulin
regimens (human neutral protamine Hagedorn [NPH], long-acting
analogue or premixed), and at elevated cardiovascular risk, were
randomized double-blind to receive either liraglutide ≤1.8 mg once
daily or placebo as add-on to standard of care. In total, 9430 participants
were enrolled at 410 centers across 32 countries. All participants gave
informed consent. The trial was approved by local ethical committees
and institutional review boards, and was conducted in accordance with
the Declaration of Helsinki.
2.1. Participants
Two groups of participants were recruited. The prior CVD group
(n = 7592, 81.3% of total cohort) comprised participants ≥50 years old
with prior myocardial infarction (MI); ischemic heart disease; stroke;
transient ischemic attack; arterial revascularization; N50% stenosis of
coronary, carotid or lower extremity arteries; history of symptomatic
chronic heart disease; asymptomatic cardiac ischemia; chronic heart
failure (New York Heart Association [NYHA] classes II–III); or chronic
renal failure (assessed by GFR b60 ml/min/1.73 m2 using Modiﬁcation
of Diet in Renal Disease [eGFR-MDRD] or Cockcroft–Gault formula). The
second group (n = 1748, 18.7% of total cohort) included participants
≥60 years oldwithout prior CVD, who had one ormore of the following
cardiovascular risk factors: microalbuminuria, proteinuria, hyperten-sion and left ventricular hypertrophy, left ventricular dysfunction or
ankle brachial index b0.9. The protocol stipulated target enrollment of
≥400 individuals with eGFR-MDRD 30–59 ml/min/1.73 m2) and 200
with eGFR-MDRD b30 ml/min/1.73 m2. Only the prior CVD group
enrolled participants with eGFR b60 ml/min/1.73 m2 (Marso et al.,
2013). Therefore, only the baseline data (i.e., prior to initiation of trial
drug) from the prior CVD group were evaluated here as this was the
population of interest.
2.2. Renal parameters
Serum and urine creatinine concentrations were determined by the
modiﬁed kinetic Jaffe reaction and all other parameters by an enzymatic
colorimetric assay (Roche Diagnostics, Mannheim, Germany) and
performed centrally (ICON PLC, Dublin, Ireland).
GFR was estimated using the standard MDRD equation (Levey et al.,
1999) and the Chronic Kidney Disease Epidemiology Collaboration
(CKD-EPI) equation (Levey et al., 2009).
Participants were asked to bring ﬁrst morning urine to their
randomization visit, which was sent to a central laboratory for
albumin-to-creatinine ratio (ACR) assessment.
2.3. Deﬁnitions
eGFR levels were categorized as follows: stage 1 (≥90 ml/min/
1.73 m2), stage 2 (60–89 ml/min/1.73 m2), stage 3 (30–59 ml/min/
1.73 m2; 3a, 45–59 ml/min/1.73 m2; 3b, 30–44 ml/min/1.73 m2), or
stage 4/5 (b30 ml/min/1.73 m2) (Canadian Diabetes Association Clinical
Practice Guidelines Expert Committee, 2013; Kidney Disease: Improving
Global Outcomes CKDWork Group, 2013).
Urine ACR levels were categorized as follows: normal (normoalbu-
minuria b3.0 mg/mmol [approximate equivalent b30 mg/g]), mildly
to moderately increased (microalbuminuria 3.0–30.0 mg/mmol
[30–300 mg/g]) and severely increased (macroalbuminuria
N30.0 mg/mmol [N300 mg/g]).
CKD was deﬁned as presence of eGFR-MDRD b60 ml/min/1.73 m2
and/or urine ACR ≥3.0 mg/mmol (Kidney Disease: Improving Global
Outcomes (KDIGO) CKD Work Group, 2013).
Target HbA1c was deﬁned as ≤7% (53 mmol/mol) in this analysis.
Blood pressure (BP) was recorded at screening, usually as an average
of two BPmeasurements. Hypertensionwas deﬁned in this analysis as
systolic BP (SBP) ≥140 mm Hg and/or diastolic BP (DBP) ≥80 mm Hg.
Intensively treated hypertension was deﬁned as prescription of ≥3
antihypertensive medications, including ACE inhibitors (ACE-Is),
angiotensin receptor blockers (ARBs), calcium channel blockers,
diuretics and others.
The primary eGFR-MDRDmodelwas deﬁned as an eGFR b60 ml/min/
1.73 m2 and/or ACR ≥3.0 mg/mmol; the four other models (sensitivity
analyses) included reduced eGFR-CKD-EPI and/or increased ACR, reduced
eGFR-MDRD, reduced eGFR-CKD-EPI, or increased ACR.
2.4. Statistical analysis
Distributions of continuous variables are described by mean (SD),
and median (interquartile range [IQR]). Categorical variables are listed
as numbers and percentages. Comparisons of continuous or categorical
variables were performed by t-test or χ2 test. A P-value b0.05 was
considered statistically signiﬁcant.
Factors potentially associatedwith the prevalence of CKD in theprior
CVD group were investigated using multivariate logistic regression
analyses and expressed as adjusted ORs with 95% CIs. As previously
described, the primary model was eGFR-MDRD b60 ml/min/1.73 m2
and/or ACR ≥3.0 mg/mmol, and results from four other models
(sensitivity analyses) are also presented. All analyses were performed
using SAS version 9.3 (SAS Institute, Cary, NC, USA) and data available at
the time, prior to the end of the study.
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3.1. Baseline demographic and laboratory characteristics
Baseline demographic and laboratory characteristics of the subset of
LEADER participants with prior CVD are presented by gender in Table 1.
Nearly two-thirds of participants were male (66.5%), mean age was
64 years, mean diabetes duration was 12.8 years and mean HbA1c was
8.7% (71 mmol/mol). Within the male and female populations, there
were comparable proportions of participants with CKD. Among the
population with prior CVD, 93.2% had hypertension, and 20.9% had
intensively treated hypertension (Table 2). Most of the populationwith
prior CVD (78.7%) were White, 9.9% were Asian, 7.0% were Black and
4.3% were of another race (Table 2).
3.2. Renal function
The prevalence of CKD in the subset of LEADER participants with
prior CVD was 51.9%.
Theproportions of participantswith stage 1–5eGFR-MDRDare shown
in Table 1 (data for stage 4 and 5 categories are combined). The CKD-EPI
equation identiﬁed more people with normal or severely reduced
eGFR and fewer with mild-to-moderately reduced eGFR (Table 1),
but there was a strong correlation between the results of the two
methods (r = 0.937, P b 0.0001).
The prevalence of normal, mildly-to-moderately increased and
markedly increasedACRwas50.2%, 33.6% and16.3%, respectively (Table1).
3.3. Renal function by gender and race
Fig. 1 shows eGFR-MDRD by gender and race. In Black individuals
of both genders and women of ‘other’ race, eGFR revealed an
asymmetric distribution with a curve shifted to the left. In Asian
women, eGFR peaked at approximately 100 ml/min/1.73 m2. In all
other groups, eGFR showed a normal distribution with a peak at
approximately 80 ml/min/1.73 m2. Distributions of renal function
deﬁned by eGFR-MDRD categories were broadly similar among races
and between genders (Supplementary Fig. 1).Table 1
Demographic and laboratory characteristics of the prior CVD group by gender.
Parametersa Full (n = 7592)
Age, y 63.9 (7.6); 64.0 (11
Body weight, kg 92.3 (20.9); 90.1 (2
BMI, kg/m2 32.5 (6.3); 31.7 (8.
Waist circumference, cm 110.1 (16.1); 108.5
HbA1c, % (mmol/mol) 8.67 (1.51); 8.30 (1
71.2 (16.5); 67.2 (1
Duration of diabetes, y 12.8 (8.1); 11.4 (10
SBP, mm Hg 137.1 (18.8); 136.0
DBP, mm Hg 77.5 (10.6); 78.0 (1
Heart rate, beats/min 72.7 (11.3); 72.0 (1
Creatinine, μmol/l 89.5 (39.6); 80.0 (3
Renal function category (based on eGFR ml/min per 1.73 m2 by MDRD; and CKD-EPI equ
Normal (≥90) 34.5; 39.3
Mild (60–89) 38.8; 35.6
Moderate (30–59) 24.4; 22.6
Severe (b30) 2.3; 2.6
ACR (mg/mmol; n = 6189; male: 4247, female: 1942), %
Normal (b3.0) 50.2
Mild-moderately elevated (3.0–30.0) 33.6
Markedly elevated (N30.0) 16.3
Lipids, mmol/l
LDL cholesterol 2.28 (0.92); 2.12 (1
HDL cholesterol 1.16 (0.31); 1.11 (0
Triglycerides 2.07 (1.59); 1.71 (1
ACR, urinary albumin-to-creatinine ratio; BMI, bodymass index; BP, blood pressure; CKD-EPI
diastolic blood pressure; eGFR, estimated GFR; IQR, interquartile range; MDRD, Modiﬁcatio
a Data are given as mean (SD); median (IQR) unless otherwise indicated.3.4. Renal function by region
Fig. 2 shows CKD prevalence by region. CKD was highest in
participants from Asia (75.8%) and lowest in participants from Europe
(43.7%) or the Middle East (43.4%).
3.5. Baseline characteristics of participants with or without CKD
Baseline characteristics of participants with and without CKD are
shown in Table 2. We observed an increase in age and diabetes duration
in patients with CKD (Table 2). CKD was more common in the
underweight (BMI ≤18.5 kg/m2), normal-weight (BMI 18.5–25 kg/m2)
and morbidly obese (BMI N40 kg/m2) groups than in the overweight or
other obese groups (BMI 25–40 kg/m2) (Table 2). Both hypertension and
intensively treated hypertension, as deﬁned by use of antihypertensive
drugs, were more common in patients with CKD (Table 2). Compared to
patients without CKD,more patients with CKDwere treatedwith insulin
only or insulin plus OADs, ARBs and diuretics. Fewer patients in the CKD
groupwere treatedwith ACE-Is or acetyl salicylic acid (ASA) (Table 2). In
the full population with prior CVD, 49.1% and 28.9% of patients were
treatedwith either ACE-Is or ARBs, respectively, andonly 2.8% of patients
were treated with both (Supplementary Table 1).
3.6. Factors associated with CKD: primary model
A multivariable logistic regression model was used to investigate the
association of different baseline factors with the prevalence of CKD
(Table 3, Supplementary Table 2). Factors associated with an increase in
the likelihood of CKD were as follows: more advanced age, male, longer
diabetes duration, higher HbA1c, higher SBP, higher heart rate, higher
triglycerides, greater number of antihypertensive medications, being
a current smoker, having an abnormal ECG (determined by the
investigator), living in Asia, Australia, North America, Africa or South
America (but not Middle East) versus living in Europe, type of diabetes
treatment (treatmentwith basal insulin versus no insulin; treatmentwith
no OAD [mostly treatment with insulin, or dietary intervention with no
OAD] versus N2 OADs) and concomitant medications (not being on a
beta-blocker, ASA or ACE-I). Factors associated with a decrease in theFemale (n = 2544) Male (n = 5048)
.0) 64.0 (7.7); 63.0 (11.0) 63.9 (7.5); 64.0 (11.0)
6.9) 85.5 (19.6); 83.1 (25.2) 95.7 (20.7); 93.3 (26.3)
0) 33.8 (6.9); 33.0 (9.0) 31.9 (5.9); 31.2 (7.4)
(19.0) 107.9 (15.7); 107.0 (19.3) 111.2 (16.1); 109.2 (19.3)
.80) 8.77 (1.56); 8.40 (2.00) 8.61 (1.48); 8.20 (1.80)
9.7) 72.4 (17.1); 68.3 (21.9) 70.6 (16.2); 66.1 (19.7)
.3) 13.6 (8.6); 12.0 (11.3) 12.4 (7.9); 11.1 (10.2)
(23.0) 138.5 (19.6); 137.5 (24.5) 136.4 (18.3); 135.0 (23.0)
4.5) 77.6 (10.9); 78.5 (14.5) 77.5 (10.4); 78.0 (14.3)
6.0) 73.9 (10.9); 73.0 (14.0) 72.0 (11.5); 72.0 (16.0)
7.0) 78.6 (37.6); 68.0 (34.5) 95.1 (39.3); 85.0 (37.0)
ations), %
32.7; 39.3 35.4; 39.2
36.8; 32.8 39.8; 37.0
27.5; 24.8 22.9; 21.5
3.0; 3.2 2.0; 2.3
52.2 49.2
31.3 34.6
16.6 16.2
.14) 2.51 (0.98); 2.36 (1.25) 2.16 (0.86); 2.01 (1.03)
.37) 1.29 (0.33); 1.25 (0.40) 1.09 (0.29); 1.06 (0.33)
.25) 2.02 (1.31); 1.73 (1.16) 2.10 (1.72); 1.70 (1.29)
, Chronic Kidney Disease Epidemiology Collaboration; CVD, cardiovascular disease; DBP,
n of Diet in Renal Disease study; SBP, systolic blood pressure; SD, standard deviation.
Table 2
Baseline variables in the LEADER prior CVD population with or without CKD.a
Parameters, % Full prior CVD (n = 7592) No CKD (n = 3650) CKD (n = 3942)
Categorical variablesb
Gender
Female, n (%) 2544 (33.5) 1236 (33.9) 1308 (33.2)
Male, n (%) 5048 (66.5) 2414 (66.1) 2634 (66.8)
Age group, y
50–59, n (%) 2295 (30.2) 1331 (36.5) 964 (24.5) [42.0]c
60–69, n (%) 3502 (46.1) 1664 (45.6) 1838 (46.6) [52.5]c
70–79, n (%) 1618 (21.3) 616 (16.9) 1002 (25.4) [61.9]c
≥80, n (%) 173 (2.3) 39 (1.1) 138 (3.5) [78.0]c
BMI group, kg/m2
≤18.5, n (%) 7 (0.1) 1 (0.0) 6 (0.2) [85.7]c
N18.5, ≤25, n (%) 686 (9.0) 274 (7.5) 412 (10.5) [60.1]c
N25, ≤30, n (%) 2151 (28.3) 1053 (28.8) 1098 (27.9) [51.0]c
N30, ≤35, n (%) 2452 (32.3) 1196 (32.8) 1256 (31.9) [51.2]c
N35, ≤40, n (%) 1405 (18.5) 714 (19.6) 691 (17.5) [49.2]c
N40, n (%) 882 (11.6) 407 (11.2) 475 (12.0) [53.9]c
Diabetes duration, y
≤5, n (%) 1178 (15.5) 716 (19.6) 462 (11.7) [39.2]c
N5, ≤10, n (%) 1934 (25.5) 1032 (28.3) 902 (22.9) [46.6]c
N10, ≤15, n (%) 1847 (24.3) 911 (25.0) 936 (23.7) [50.7]c
N10, ≤20, n (%) 1244 (16.4) 498 (13.6) 746 (18.9) [60.0]c
N20, n (%) 1385 (18.2) 492 (13.5) 893 (22.7) [64.5]c
Race
Asian, n (%) 753 (9.9) 218 (6.0) 535 (13.6)
Black, n (%) 535 (7.0) 227 (6.2) 308 (7.8)
White, n (%) 5974 (78.7) 3041 (83.3) 2933 (74.4)
Other, n (%) 330 (4.3) 164 (4.5) 166 (4.2)
Region
Europe, n (%) 2929 (38.6) 1649 (45.2) 1280 (32.5)
North America, n (%) 2342 (30.8) 1038 (28.4) 1304 (33.1)
South America, n (%) 868 (11.4) 383 (10.5) 485 (12.3)
Middle East, n (%) 422 (5.6) 239 (6.5) 183 (4.6)
Asia, n (%) 592 (7.8) 143 (3.9) 449 (11.4)
Africa, n (%) 244 (3.2) 116 (3.2) 128 (3.2)
Australia, n (%) 195 (2.6) 82 (2.2) 113 (2.9)
Smoking
Current smoker, n (%) 927 (12.2) 449 (12.3) 478 (12.1)
Previous smoker, n (%) 3670 (48.3) 1806 (49.5) 1864 (47.3)
Never smoked, n (%) 2995 (39.4) 1395 (38.2) 1600 (40.6)
Use of antihypertensive drugs
Yes, n (%) 7077 (93.2) 3363 (92.1) 3714 (94.2)
No, n (%) 515 (6.8) 287 (7.9) 228 (5.8)
Intensively treated HT (prescribed ≥3 antihypertensive drugs)
Yes, n (%) 1583 (20.9) 608 (16.7) 975 (24.7)
No, n (%) 6009 (79.1) 3042 (83.3) 2967 (75.3)
ECG
Missing n (%) 32 (0.4) 15 (0.4) 17 (0.4)
Normal n (%) 2877 (37.9) 1496 (40.3) 1381 (35.6)
Abnormal n (%) 4683 (61.7) 2203 (59.5) 2480 (64.0)
Previous diabetes treatment
None/diet, n (%) 405 (5.3) 163 (4.5) 242 (6.1)
Insulin only, n (%) 596 (7.9) 163 (4.5) 433 (11.0)
OAD only, n (%) 3927 (51.7) 2100 (57.5) 1827 (46.3)
Insulin + OADs, n (%) 2664 (35.1) 1224 (33.5) 1440 (36.5)
Number of OADs (‘OAD only’)
1 OAD, n (%) 1539 (39.2) 860 (41.0) 679 (37.2)
2 OADs n (%) 2131 (54.3) 1120 (53.3) 1011 (55.3)
N2 OADs, n (%) 257 (6.5) 120 (5.7) 137 (7.5)
Type of insulin (‘insulin only’ plus ‘insulin + OADs’)
Basal, n (%) 2622 (80.4) 1135 (81.8) 1487 (79.4)
Premixed, n (%) 599 (18.4) 234 (16.9) 365 (19.5)
Basal + premixed, n (%) 39 (1.2) 18 (1.3) 21 (1.1)
HbA1c on target (b7% [53 mmol/mol]), n (%) 580 (7.6) 305 (8.4) 275 (7.0)
Antihypertensive drugs
ACE-I, n (%) 3935 (51.8) 1986 (54.4) 1949 (49.4)
ARB, n (%) 2404 (31.7) 982 (26.9) 1422 (36.1)
Diuretic, n (%) 3350 (44.1) 1408 (38.6) 1942 (49.3)
Other concomitant medications
Statins, n (%) 6000 (79.0) 2879 (78.9) 3121 (79.2)
Other lipid-lowering, n (%) 163 (2.1) 80 (2.2) 83 (2.1)
ASA, n (%) 5103 (67.2) 2542 (69.6) 2561 (65.0)
NSAID, n (%) 80 (1.1) 44 (1.2) 36 (0.9)
Previous comorbidities (%)
MI, n (%) 1471 (19.4) 754 (20.7) 717 (18.2)
Angina, n (%) 2572 (33.9) 1453 (39.8) 1119 (28.4)
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Table 2 (continued)
Parameters, % Full prior CVD (n = 7592) No CKD (n = 3650) CKD (n = 3942)
Stroke, n (%) 1097 (14.4) 563 (15.4) 534 (13.5)
Gallstones, n (%) 889 (11.7) 403 (11.0) 486 (12.3)
Continuous variablesd
HbA1c (%) 8.67 (1.51); 8.3 (1.8) 8.50 (1.37); 8.1 (1.7) 8.82 (1.61); 8.4 (2.1)
HbAc (mmol/mol) 71.3 (16.50); 67.2 (19.6) 69.4 (14.97); 65.0 (18.5) 72.9 (17.60); 68.3 (22.9)
Lipids (mmol/l)
Triglycerides 2.07 (1.59); 1.71 (1.25) 1.99 (1.44); 1.64 (1.19) 2.15 (1.72); 1.76 (1.29)
HDL cholesterol 1.16 (0.31); 1.11 (0.37) 1.17 (0.31); 1.11 (0.36) 1.15 (0.31); 1.11 (0.38)
LDL cholesterol 2.28 (0.92); 2.12 (1.14) 2.26 (0.90); 2.12 (1.12) 2.29 (0.93); 2.11 (1.15)
ACE-I, ACE-inhibitor; ARB, angiotensin receptor blocker; ASA, acetylsalicylic acid; BMI, body mass index; CKD, chronic kidney disease; CKD-EPI, Chronic Kidney Disease Epidemiology
Collaboration; CVD, cardiovasculardisease; ECG, electrocardiogram; eGFR, estimatedGFR;HbA1c, glycatedhemoglobin;HDL, high-density lipoprotein;HT, hypertension; IQR, interquartile
range; LDL, low-density lipoprotein; MDRD, Modiﬁcation of Diet in Renal Disease study; MI, myocardial infarction; NSAID, non-steroid anti-inﬂammatory drug; OAD, oral antidiabetic
drug; SD, standard deviation.
a CKD deﬁned as eGFR b60 ml/min per 1.73 m2 using the MDRD equation and/or ACR ≥3.0 mg/mmol.
b Each factor, such as previous diabetes treatment, contains different categories that are exhaustive and mutually exclusive.
c CKD prevalence in square brackets calculated from patients (n) per group.
d Data are given as mean (SD); median (IQR).
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treatment and history of MI, angina or stroke (Supplementary Table 2).3.7. Factors associated with CKD: sensitivity analyses
Results of multivariable logistic regressionmodel sensitivity analyses
are summarized in Supplementary Table 2 and presented in detail in
Supplementary Tables 3–6.Fig. 1. eGFR-MDRD in LEADER participants with prior CVD at baseline by race and gender. Rac
CVD, cardiovascular disease; eGFR, estimated glomerular ﬁltration rate; MDRD, ModiﬁcatioBrieﬂy, the present study identiﬁed several factors associated with
CKD in patients with T2DM and prior CVD, using ﬁve different models.
Baseline factors associated with higher prevalence of CKD across all
models were: more advanced age; longer diabetes duration; higher SBP;
higher triglycerides; greater number of antihypertensive medications;
living inNorthAmerica, SouthAmerica orAsia versus living inEurope; no
OAD treatment (mostly insulin treatment) versus N2 OADs; treatment
with basal insulin versus no insulin; and not being on a beta-blocker
or ACE-I.e information was collected using the following categories: Asian, Black, White or other.
n of Diet in Renal Disease study.
Fig. 2. The prevalence of CKD⁎ in LEADER participants with prior CVD at baseline by region. ⁎ CKD deﬁned as eGFR-MDRD b60 ml/min per 1.73 m2 and/or ACR ≥3.0 mg/mmol.
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4.1. Study objectives and main results
We report thatmore than half of the LEADER populationwith prior
CVD had some degree of CKD prior to initiation of the trial drug.
Our ﬁndings demonstrate that the duration of diabetes is a factor
associated with CKD, which is consistent with several other studies
(Parving et al., 2006; Yokoyama et al., 2009). Parving et al. showed that
duration of diabetes was a signiﬁcant (P b 0.0001) risk factor for micro-
or macroalbuminuria (an early marker of diabetic nephropathy and
leading cause of CKD), in White, Black or Asian patients with TD2M.
In addition, Yokoyama et al. established that the duration of diabetes
was signiﬁcantly (P = 0.037) associated with CKD in Japanese patients
with TD2M.
Putting our study into context, the prevalence of those with CKD
(51.9%) is higher than thoseof theRenal InsufﬁciencyAndCardiovascular
Events (RIACE) study's CKD population (37.6%) (Pugliese et al., 2014),
which examined a cohort of 15,773 Italian subjects with T2DM. The
differences in prevalence of CKD and between the two studies may be
attributable, at least in part, to the randomized trial inclusion criteria and
observational study designs of LEADER and RIACE, respectively.
Increasing DBP and history of angina or stroke were associated
with a decreasing prevalence of CKD across all ﬁve models. The
association between higher DBP and lower CKD prevalence might
appear counter to the associations between elevated SBP and
increased CKD prevalence. However, a meta-analysis of people
without diabetes (Jafar et al., 2003), and the Systolic Hypertension
in the Elderly Program (SHEP) (Young et al., 2002), both indicated
that higher SBP, but not higher DBP, is strongly associated with
progression of kidney disease.
Our ﬁnding that not being on a beta-blocker or ACE-I is associated
with higher prevalence of CKD is consistent with previous observations
that BP-lowering interventions prevent renal adverse events (Lv et al.,
2012). Increasing numbers of BP-lowering medications were also
associated with increased CKD prevalence in patients with T2DM and
prior CVD, suggesting that annual screening for renal impairment is
even more important in people with T2DM who also have intensively
treated hypertension. Moreover, studies with a beta-blocker, carvedilol
demonstrated attenuated increases in albuminuria in patientswith CKD
with hypertension. The absence of a beta-blockermay therefore remove
any renoprotection, subsequently elevating the riskof CKD(Bakris,Hart,
& Ritz, 2006).
Several studies have shown that prior CVD was associated with
increased CKD prevalence and risk (Elsayed et al., 2007;
Rodriguez-Poncelas et al., 2013). Interestingly, in our study, having
a history of angina or stroke was associated with decreased CKD
prevalence across all ﬁve models.We also found a positive correlation between more advanced age
and CKD in patients with T2DM with prior CVD across all models. This
alignswith data frombroader populations. For example, in theNHANES,
the prevalence of diabetic kidney disease was highest in those aged
≥65 years, in both thegeneral population and thosewithT2DM(deBoer
et al., 2011). Indeed, Coresh et al. (2003) showed that the creatinine
clearance estimates demonstrated a more marked decrease with age
in patients with CKD. Yokoyama et al. established that age was
signiﬁcantly (P b 0.0001) associated with CKD in Japanese patients
with TD2M (Yokoyama et al., 2009). Another study, evaluating
outcomes of CKD in US veterans, found that, among those with
comparable levels of eGFR, older patients had higher rates of death
and lower rates of ESRD than younger individuals (O'Hare et al., 2007),
suggesting that age may be an important modiﬁer in CKD. These
ﬁndings challenge taking a uniform, ‘age-neutral’ approach to manage-
ment of CKD, and underline the critical need for better prognostic tools
to identify older individuals who will progress to ESRD.
According to regression models, the present study found no
differences in the distribution of CKD between people of Asian, Black or
‘other’ raceversus thoseofWhite racewithT2DMandprior CVD, although
the odds of having eGFR-CKD-EPI b60 ml/min/1.73 m2 were elevated
in people from ‘other’ race versus those of White race (Supplementary
Table 2).
Our data revealed an increased prevalence of CKD among people
with T2DM and prior CVD from outside Europe, except the Middle
East. This ﬁnding supports the suggestion that rates of CKD continue
to be higher in developing countries. Given the large economic and
health burden of diabetes and its complications, early and frequent
screening for diabetes and renal impairment is recommended, and the
focus should be on disease prevention.
A signiﬁcant association between higher BMI and CKD was not
consistently observed across all models in the present analysis. The
obesity cohort of the Framingham Heart Study had increased odds of
developing stage 3 CKD relative toparticipantswithnormal BMI, but the
additional risk disappeared after adjustment for known cardiovascular
risk factors, suggesting the relationship between obesity and CKD may
be mediated via cardiovascular risk factors (Foster et al., 2008). All
patients in our study already had elevated cardiovascular risk, which
could explain, in part, the inconsistent observations for higher BMI and
CKD. Additionally, in a multinational population, BMI might be a good
indicator for obesity.
In the present study, we used the eGFR-MDRD equation in our
primary statistical model and the CKD-EPI formula in our sensitivity
analyses, with a strong correlation evident between the results of the
two methodologies. In the present study, however, estimation of GFR
using the CKD-EPI equation identiﬁed a higher percentage of people
with normal renal function and slightly more with severe renal
impairment. The accuracy of these two equations in estimating renal
Table 3
Multivariable logistic regression modelling the probability of CKD (based on eGFR-MDRD
b60 ml/minper1.73 m2and/orurineACR≥3.0 mg/mmol) in thepriorCVDgroupof LEADER.
Factor (level) OR; 95% CI P-value
Age (per SD increase, y) 1.417; 1.337–1.501 b0.0001
Male gender (ref. female) 1.242; 1.105–1.397 0.0003
BMI (per SD increase, kg/m2) 1.028; 0.971–1.088 0.3457
Diabetes duration (per SD increase, y) 1.203; 1.137–1.272 b0.0001
HbA1c (per SD increase, %) 1.259; 1.189–1.334 b0.0001
Not at HbA1c target (ref. HbA1c ≤7%) 0.824; 0.675–1.006 0.0574
SBP (per SD increase, mm Hg) 1.290; 1.202–1.385 b0.0001
DBP (per SD increase, mm Hg) 0.887; 0.824–0.955 0.0015
No HT (ref. ≥140/80 mm Hg) 1.011; 0.871–1.173 0.8867
Number of antihypertensives (per medication) 1.529; 1.396–1.676 b0.0001
Heart rate (per SD increase, beats per minute) 1.058; 1.003–1.1117 0.0380
Triglycerides (per SD increase, mmol/l) 1.209; 1.141–1.284 b0.0001
Current smoker (ref. never smoked) 1.271; 1.073–1.507 0.0056
Previous smoker (ref. never smoked) 1.002; 0.894–1.123 0.9752
Race (ref. White)
Asian 1.354; 0.953–1.926 0.0905
Black 0.917; 0.743–1.134 0.4244
Other 0.856; 0.657–1.115 0.2500
Region (ref. Europe)
North America 1.526; 1.339–1.739 b0.0001
South America 1.397; 1.159–1.683 0.0004
Middle East 1.214; 0.967–1.523 0.0939
Asia 4.357; 2.907–6.537 b0.0001
Africa 1.500; 1.098–2.050 0.0109
Australia 1.574; 1.137–2.184 0.0064
Diabetes medications
No OADa (ref. N2 OADs) 1.743; 1.317–2.306 0.0001
1 OAD (ref. N2 OADs) 1.019; 0.794–1.308 0.8798
2 OADs (ref. N2 OADs) 0.927; 0.725–1.186 0.5468
Basal and premixed insulin (ref. no insulin) 0.759; 0.382–1.518 0.4311
Basal insulin (ref. no insulin) 1.125; 1.006–1.259 0.0397
Premixed insulin (ref. no insulin) 1.099; 0.895–1.350 0.3696
Abnormal ECG (ref. normal ECG) 1.165; 1.050–1.294 0.0041
Comorbidconditions (ref. nohistoryof the condition)
MI 0.690; 0.597–0.797 b0.0001
Angina 0.560; 0.497–0.632 b0.0001
Stroke 0.706; 0.611–0.815 b0.0001
Gallstones 1.098; 0.937–1.287 0.2492
Concomitant medications (ref. yes)
No beta-blocker 1.507; 1.302–1.745 b0.0001
No ASA 1.157; 1.035–1.292 0.0101
No diuretic 0.723; 0.651–0.804 b0.0001
No ACE-I 1.342; 1.148–1.569 0.0002
No ARB 1.114; 0.942–1.318 0.2091
No statin 0.943; 0.828–1.073 0.3701
No NSAID 1.507; 0.926–2.470 0.1007
ACE-I, ACE-inhibitor; ACR, urinary albumin-to-creatinine ratio; ARB, angiotensin receptor
blocker;ASA, acetylsalicylic acid; BMI, bodymass index;CKD, chronic kidney disease;DBP,
diastolic BP; ECG, electrocardiogram; eGFR, estimated GFR; HbA1c, glycated hemoglobin;
HT, hypertension; MDRD, Modiﬁcation of Diet in Renal Disease study; MI, myocardial
infarction; NSAID, non-steroid anti-inﬂammatory drug; OAD, oral antidiabetic drug; SBP,
systolic blood pressure; SD, standard deviation.
a Mostly insulin treatment, or dietary intervention with no OAD.
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disparity between the two equations, in the RIACE cohort, those with
impaired eGFR or CKD with the MDRD study equation only showed
lower CVD prevalence rates and coronary heart disease risk scores.
This trend was predominantly driven by female gender, younger age
and shorter diabetes duration, as compared with those with both
formulas; however, in contrast, the opposite trends were observed in
patients in the same categories with the CKD-EPI equation only
(Pugliese et al., 2014). Indeed, CKD prevalence, gender ratios, and
Kidney Disease: Improving Global Outcomes (KDIGO) composite risk
groupings can vary widely depending on the equation used
(Kitiyakara et al., 2012). New markers, such as cystatin C, have been
suggested to assess more accurately the wider ranges of GFR in
multi-ethnic countries (Ho & Teo, 2010). In this regard, urine albumin
concentration and ACR have been established as acceptable tests for
the screening of albuminuria in Indo-Asian patients (Jafar, Chaturvedi,Hatcher, & Levey, 2007). In a study of modiﬁed equations developed in
Asiatic populations, Liu et al. (2014) found limitations in such equations.
Some studies, however, suggest that the CKD-EPI formula has improved
accuracy, especially athigherGFRs (Stevens et al., 2010; Teo et al., 2011).
Further, Teoet al. advised against usingethnic adjustment for estimating
GFR in multi-ethnic Asian patients with CKD; based on these data, we
did not use these adjustments in our study.
Half of our global T2DM population with prior CVD had an abnormal
ACR (normal, 50%; microalbuminuria, 34%; macroalbuminuria, 16%).
Our results are consistent with those from the cross-sectional DEMAND
study, inwhichone randomurinaryACRwasmeasured in24,151patients
with T2DM from 33 countries, and the global prevalence of normo-,
micro- and macroalbuminuria was 51%, 39% and 10%, respectively
(Parving et al., 2006).
Albuminuria is a marker for glomerular injury as well as endothelial
dysfunction and is often an early clinical indicator of CKD (Bakris &
Molitch, 2014). However, impaired GFR may be observed without
substantial elevation in ACR in patients with T2DM (Coresh et al., 2003;
de Boer et al., 2011). In our cohort, at baseline, nearly 60% of those
with normal ACR had mild-to-moderately decreased eGFR-MDRD
(Supplementary Fig. 2), conﬁrming that nonalbuminuric renal impair-
ment in patients with diabetes is not uncommon. This ﬁnding was
supported by several studies in which diminished GFR occurred in
nonalbuminuric patients (Kramer, Nguyen, Curhan, & Hsu, 2003;
Pugliese et al., 2014; Retnakaran et al., 2006; Thomas et al., 2009). In
terms of prevalence, in a nationally representative cohort of 3893
patients with T2DM, Thomas et al. (2009) established that of the 23.1%
of individuals with T2DMwho had eGFR b60 ml/min/1.73 m2, 55% had
nonalbuminuric renal impairment.
The frequent manifestation of impaired GFR supports current
guidelines recommending screening for albuminuria in addition to GFR
(American Diabetes Association, 2016; Canadian Diabetes Association
Clinical Practice Guidelines Expert Committee, 2013; Kidney Disease:
Improving Global Outcomes (KDIGO) CKDWork Group, 2013).
There are also people with increased ACR, but normal GFR, as in the
cohort studied here, in which approximately one-third of those with
mild-to-moderately increased ACR and 16% of those with markedly
increasedACR had normal eGFR-MDRD (Supplementary Fig. 2). Current
guidelines from the American Diabetes Association (American Diabetes
Association, 2016) andUSNational Kidney Foundation (NationalKidney
Foundation, 2012) recommendmeasuring albuminuriamore than once,
and state that two of three samples should be elevated over 3–6 months
for conﬁrmation of increased albuminuria (Tuttle et al., 2014). In
LEADER, urine specimens were collected at randomization and then
yearly for the duration of the trial (Marso et al., 2013).
It is clear that the relationship of ACR to ESRD and CVD risk is a
continuum, starting from ‘normal’ levels. However, the development
of microalbuminuria into progressive nephropathy is not inevitable,
and glucose, BP, lipid control and use of ACE-I or ARB are crucial in
delaying its progression.
The strengths of this study include using broad data, simultaneously
examining ACR and eGFR in a central laboratory, and using several
deﬁnitions of CKD. LEADER enrolled subjects with prior CVD and
consisted of a diverse, multinational population. The large sample size
permitted us toperformcategorical analyses for age at10-year intervals,
for BMI from lean to morbid obesity and for diabetes duration from 5
to N20 years.
4.2. Limitations
Thepresent study includes limitations thatwarrant discussion. Some
of the factors associated with CKD may have a common background,
e.g., more advanced age and longer diabetes duration. ACR was
measured once at randomization. As this study uses baseline data, it is
not possible to establish any direction of causality. It should also be
noted that we cannot exclude the etiologies of CKD other than diabetes
1638 I. Satman et al. / Journal of Diabetes and Its Complications 30 (2016) 1631–1639in the population studied. Due to the large sample size, some of the
associations identiﬁed may be statistically signiﬁcant but not clinically
relevant. For example, while a history of MI or stroke is a factor
associated with a decrease in the probability of having CKD, the
prevalence of acute MI or stroke is not markedly different between
patients with or without CKD. LEADER speciﬁcally enrolled subjects at
high cardiovascular risk, and this study included only the prior CVD
group, therefore, our results are only directly applicable to patientswith
T2DM and CVD. Finally, the study design also dictates that the results
presented apply to moderate to severe CKD, but not mild or end-stage
renal disease.
5. Conclusions
CKD prevalence is high among patients with T2DMwith prior CVD.
Age, glycemic and BP control, diabetes treatment, comorbidities and
concomitant medications used were found to be associated with CKD
prevalence. Screening for CKD in patients with T2DM and prior CVD
and enrolling patients at high risk of CKD into preventive programmes
may be warranted.
Funding
The LEADER trial was funded by Novo Nordisk. Editorial support,
provided byWatermeadowMedical, was supported by Novo Nordisk.
The authors take full responsibility for the design of this study, the
study data, and the ﬁnal contents of this manuscript.
Acknowledgments
The authors thank the LEADER trial Investigators (Marso et al., 2013),
personnel and participants. Special thanks to HenrikWachmann (Novo
Nordisk) and Kadriye Kaplan (Novo Nordisk) for performing the
statistical analyses, and to Watermeadow Medical (supported by
Novo Nordisk) for providing editorial assistance. The authors also
thankRosarioArechavaleta for reviewing a draft of thiswork and for her
helpful discussions at its conception.
Appendix A. Supplementary data
Supplementary data to this article can be found online at http://dx.
doi.org/10.1016/j.jdiacomp.2016.06.001.
References
American Diabetes Association (2016). Standards of medical care in diabetes—2016.
Diabetes Care, 39(Suppl. 1), S72–S80.
Bakris, G. L., Hart, P., & Ritz, E. (2006). Beta blockers in the management of chronic
kidney disease. Kidney International, 70, 1905–1913.
Bakris, G. L., & Molitch, M. (2014). Microalbuminuria as a risk predictor in diabetes: the
continuing saga. Diabetes Care, 37, 867–875.
CanadianDiabetes AssociationClinical PracticeGuidelines Expert Committee (2013). Chronic
kidney disease in diabetes. Canadian Journal of Diabetes, 37(Suppl. 1), S129–S136.
Chandie Shaw, P. K., Vandenbroucke, J. P., Tjandra, Y. I., Rosendaal, F. R., Rosman, J. B.,
Geerlings, W., et al. (2002). Increased end-stage diabetic nephropathy in Indo-Asian
immigrants living in the Netherlands. Diabetologia, 45, 337–341.
Coresh, J., Astor, B. C., Greene, T., Eknoyan, G., & Levey, A. S. (2003). Prevalence of
chronic kidney disease and decreased kidney function in the adult US population:
Third National Health and Nutrition Examination Survey. American Journal of
Kidney Diseases, 41, 1–12.
Coresh, J., Selvin, E., Stevens, L. A., Manzi, J., Kusek, J. W., Eggers, P., et al. (2007).
Prevalence of chronic kidney disease in the United States. JAMA, 298, 2038–2047.
de Boer, I. H., Rue, T. C., Hall, Y. N., Heagerty, P. J., Weiss, N. S., & Himmelfarb, J. (2011).
Temporal trends in the prevalence of diabetic kidney disease in the United States.
JAMA, 305, 2532–2539.
Elsayed, E. F., Tighiouart, H., Grifﬁth, J., Kurth, T., Levey, A. S., Salem, D., et al. (2007).
Cardiovascular disease and subsequent kidney disease. Archives of Internal Medicine,
167(11), 1130–1136.
Emerging Risk Factors CollaborationSarwar, N., Gao, P., Seshasai, S. R., Gobin, R.,
Kaptoge, S., Di Angelantonio, E., et al. (2010). Diabetes mellitus, fasting blood
glucose concentration, and risk of vascular disease: a collaborative meta-analysis of
102 prospective studies. Lancet, 375, 2215–2222.Foster, M. C., Hwang, S. J., Larson, M. G., Lichtman, J. H., Parikh, N. I., Vasan, R. S., et al.
(2008). Overweight, obesity, and the development of stage 3 CKD: the Framingham
Heart Study. American Journal of Kidney Diseases, 52, 39–48.
Gerstein, H. C., Mann, J. F., Yi, Q., Zinman, B., Dinneen, S. F., Hoogwerf, B., ... HOPE Study
Investigators (2001). Albuminuria and risk of cardiovascular events, death, and
heart failure in diabetic and nondiabetic individuals. JAMA, 286, 421–426.
Graham, I., Atar, D., Borch-Johnsen, K., Boysen, G., Burell, G., Cifkova, R., ... European
Atherosclerosis Society (EAS) (2007). European guidelines on cardiovascular disease
prevention inclinical practice: full text. Fourth Joint Task Forceof the EuropeanSociety
of Cardiology and other societies on cardiovascular disease prevention in clinical
practice (constituted by representatives of nine societies and by invited experts).
European Journal of Cardiovascular Prevention and Rehabilitation, 14(Suppl. 2),
S1–S113.
Ho, E., & Teo, B. W. (2010). Assessing kidney function in Asia. Singapore Medical Journal,
51(11), 888–893.
International Diabetes Federation (2015). 7th Diabetes Atlas, 2015 Update Executive
Summary. (Available at http://www.diabetesatlas.org/component/attachments/?
task=download&id=90 Last accessed 29 November 2015).
Jafar, T. H., Chaturvedi, N., Hatcher, J., & Levey, A. S. (2007). Use of albumin creatinine ratio
and urine albumin concentration as a screening test for albuminuria in an Indo-Asian
population. Nephrology, Dialysis, Transplantation, 22, 2194–2200 (Epub 2007 Apr 3).
Jafar, T. H., Stark, P. C., Schmid, C. H., Landa, M., Maschio, G., de Jong, P. E., ... AIPRD Study
Group (2003). Progression of chronic kidney disease: the role of blood pressure
control, proteinuria, and angiotensin-converting enzyme inhibition: a patient-level
meta-analysis. Annals of Internal Medicine, 139, 244–252.
Kidney Disease: Improving Global Outcomes (KDIGO) CKDWork Group (2012). KDIGO
2012 clinical practice guideline for the evaluation and management of chronic
kidney disease. Kidney International(Suppl. 3), 1–150.
Kidney Disease: Improving Global Outcomes (KDIGO) CKDWork Group (2013). KDIGO
2012 clinical practice guideline for the evaluation and management of chronic
kidney disease. Kidney International(Suppl. 3), 1–150.
Kitiyakara, C., Yamwong, S., Vathesatogkit, P., Chittamma, A., Cheepudomwit, S.,
Vanavanan, S., et al. (2012). The impact of different GFR estimating equations on
the prevalence of CKD and risk groups in a Southeast Asian cohort using the new
KDIGO guidelines. BMC Nephrology, 13, 1. http://dx.doi.org/10.1186/1471-2369-13-1.
Kramer, H. J., Nguyen, Q. D., Curhan, G., & Hsu, C. Y. (2003). Renal insufﬁciency in the
absence of albuminuria and retinopathy among adults with type 2 diabetes mellitus.
JAMA, 289, 3273–3277.
Levey, A. S., Bosch, J. P., Lewis, J. B., Greene, T., Rogers, N., & Roth, D. (1999). A more
accurate method to estimate glomerular ﬁltration rate from serum creatinine: a
new prediction equation. Modiﬁcation of Diet in Renal Disease Study Group. Annals
of Internal Medicine, 130, 461–470.
Levey, A. S., Stevens, L. A., Schmid, C. H., Zhang, Y. L., Castro, A. F., 3rd, Feldman, H. I.,
Kusek, J. W., Eggers, P., Van Lente, F., Greene, T., & Coresh, J. (2009). CKD-EPI
(Chronic Kidney Disease Epidemiology Collaboration). A new equation to estimate
glomerular ﬁltration rate, Annals of Internal Medicine, 150, 604–612 (Erratum in: Ann
Intern Med, 155, 408).
Liu, X., Qiu, X., Shi, C., Huang, H., Huang, J., Li, M., et al. (2014). Modiﬁed glomerular
ﬁltration rate-estimating equations developed in Asiatic population for Chinese
patients with type 2 diabetes. International Journal of Endocrinology, 521071. http://
dx.doi.org/10.1155/2014/521071 (Published online 2014 Mar 5).
Lv, J., Neal, B., Ehteshami, P., Ninomiya, T., Woodward, M., Rodgers, A., et al. (2012).
Effects of intensive blood pressure lowering on cardiovascular and renal outcomes:
a systematic review and meta-analysis. PLoS Medicine, 9, e1001293.
Marso, S. P., Poulter, N. R., Nissen, S. E., Nauck, M. A., Zinman, B., Daniels, G. H., et al. (2013).
Design of the liraglutide effect and action in diabetes: evaluation of cardiovascular
outcome results (LEADER) trial. American Heart Journal, 166, 823–830.e5.
National Kidney Foundation (2012). KDOQI clinical practice guideline for diabetes and
CKD: 2012 update. American Journal of Kidney Diseases, 60, 850–886.
Ninomiya, T., Perkovic, V., de Galan, B. E., Zoungas, S., Pillai, A., & Jardine, M.ADVANCE
Collaborative Group. (2009). Albuminuria and kidney function independently
predict cardiovascular and renal outcomes in diabetes. Journal of the American
Society of Nephrology, 20, 1813–1821.
O'Hare, A. M., Choi, A. I., Bertenthal, D., Bacchetti, P., Garg, A. X., Kaufman, J. S., et al.
(2007). Age affects outcomes in chronic kidney disease. Journal of the American
Society of Nephrology, 18, 2758–2765.
Parsa, A., Kao, W. H., Xie, D., Astor, B. C., Li, M., Hsu, C. Y., ... CRIC Study Investigators
(2013). APOL1 risk variants, race, and progression of chronic kidney disease. The
New England Journal of Medicine, 369, 2183–2196.
Parving, H. H., Lewis, J. B., Ravid,M., Remuzzi, G., Hunsicker, L. G., & DEMAND investigators
(2006). Prevalence and risk factors formicroalbuminuria in a referred cohort of type II
diabetic patients: a global perspective. Kidney International, 69, 2057–2063.
Pugliese, G., Solini, A., Bonora, E., Fondelli, C., Orsi, E., Nicolucci, A., ... RIACE Study Group
(2014). Chronic kidney disease in type 2 diabetes: lessons from the Renal
Insufﬁciency And Cardiovascular Events (RIACE) Italian Multicentre Study.
Nutrition, Metabolism, and Cardiovascular Diseases, 24, 815–822.
Retnakaran, R., Cull, C. A., Thorne, K. I., Adler, A. I., Holman, R. R., & UKPDS Study Group
(2006). Risk factors for renal dysfunction in type 2 diabetes: U.K. Prospective
Diabetes Study 74. Diabetes, 55, 1832–1839.
Rodriguez-Poncelas, A., Garre-Olmo, J., Franch-Nadal, J., Diez-Espino, J., Mundet-Tuduri,
X., Barrot-De la Puente, J., ... RedGDPS Study Group (2013). Prevalence of chronic
kidney disease in patients with type 2 diabetes in Spain: PERCEDIME2 study. BMC
Nephrology, 14, 46. http://dx.doi.org/10.1186/1471-2369-14-46.
Samanta, A., Burden, A. C., & Jagger, C. (1991). A comparison of the clinical features and
vascular complications of diabetes between migrant Asians and Caucasians in
Leicester. U.K. Diabetes Research and Clinical Practice, 14, 205–213.
1639I. Satman et al. / Journal of Diabetes and Its Complications 30 (2016) 1631–1639Stevens, L. A., Schmid, C. H., Greene, T., Zhang, Y. L., Beck, G. J., Froissart, M., et al.
(2010). Comparative performance of the CKD-EPIdemiology Collaboration (CKD-
EPI) and the Modiﬁcation of Diet in Renal Disease (MDRD) Study equations for
estimating GFR levels above 60 ml/min/1.73 m2. American Journal of Kidney
Diseases, 56, 486–495.
Stratton, I. M., Adler, A. I., Neil, H. A., Matthews, D. R., Manley, S. E., Cull, C. A., et al.
(2000). Association of glycaemia with macrovascular and microvascular compli-
cations of type 2 diabetes (UKPDS 35): prospective observational study. BMJ, 321,
405–412.
Teo, B.W., Xu, H.,Wang,D., Li, J., Sinha, A. K., Shuter, B., et al. (2011). GFR estimating equations
in a multiethnic Asian population. American Journal of Kidney Diseases, 58, 56–63.
Thomas, M. C., Macisaac, R. J., Jerums, G., Weekes, A., Moran, J., Shaw, J. E., et al. (2009).
Nonalbuminuric renal impairment in type 2 diabetic patients and in the generalpopulation (national evaluation of the frequency of renal impairment cO-existing
with NIDDM [NEFRON] 11). Diabetes Care, 32, 1497–1502.
Tuttle, K. R., Bakris, G. L., Bilous, R.W., Chiang, J. L., de Boer, I. H., Goldstein-Fuchs, J., et al.
(2014). Diabetic kidney disease: a report from an ADA Consensus Conference.
Diabetes Care, 37, 2864–2883.
Yokoyama, H., Sone, H., Oishi, M., Kawai, K., Fukumoto, Y., Kobayashi, M., & Japan
Diabetes Clinical DataManagement Study Group (2009). Prevalence of albuminuria
and renal insufﬁciency and associated clinical factors in type 2 diabetes: the Japan
Diabetes Clinical Data Management study (JDDM15). Nephrology, Dialysis,
Transplantation, 24, 1212–1219.
Young, J. H., Klag,M. J.,Muntner, P.,Whyte, J. L., Pahor,M., & Coresh, J. (2002). Bloodpressure
and decline in kidney function: ﬁndings from the Systolic Hypertension in the Elderly
Program (SHEP). Journal of the American Society of Nephrology, 13, 2776–2782.
